Accuray Inc. (NASDAQ:ARAY) was down 1.7% on Friday . The stock traded as low as $5.23 and last traded at $5.24, with a volume of 192,332 shares traded. The stock had previously closed at $5.33.

ARAY has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Wednesday, March 30th. Morgan Stanley restated a “hold” rating on shares of Accuray in a report on Wednesday, April 27th. Finally, Brean Capital restated a “buy” rating and set a $12.00 price objective on shares of Accuray in a report on Sunday, May 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.58.

The company has a 50 day moving average price of $5.22 and a 200 day moving average price of $5.46. The company’s market cap is $433.75 million.

Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, April 26th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. The company had revenue of $105.30 million for the quarter, compared to the consensus estimate of $102.79 million. During the same period in the previous year, the firm posted ($0.04) EPS. The business’s quarterly revenue was up 8.0% compared to the same quarter last year. Equities research analysts predict that Accuray Inc. will post ($0.27) EPS for the current year.

Several hedge funds have modified their holdings of the company. Boston Partners boosted its stake in shares of Accuray by 10.8% in the fourth quarter. Boston Partners now owns 4,272,040 shares of the company’s stock valued at $28,836,000 after buying an additional 417,568 shares in the last quarter. Lapides Asset Management LLC boosted its stake in shares of Accuray by 1.8% in the fourth quarter. Lapides Asset Management LLC now owns 2,149,500 shares of the company’s stock valued at $14,509,000 after buying an additional 38,600 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Accuray by 20.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,656,069 shares of the company’s stock valued at $11,178,000 after buying an additional 286,458 shares in the last quarter. Finally, Russell Frank Co boosted its stake in shares of Accuray by 24.0% in the fourth quarter. Russell Frank Co now owns 1,028,628 shares of the company’s stock valued at $7,077,000 after buying an additional 198,874 shares in the last quarter.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.